AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20925534 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 3761
Study 20925534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3761
Study 18574364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg b.i.d. from day 1 to 3, 300 mg q.i.d. from day 4 to 6, and 600 mg t.i.d. from day 7 to 10)
Number of subjects: 13
Study 18574364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 18574364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 13
Study 15906167 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol in fast-disintegrating capsules with food
Number of subjects: 8
Study 15906167 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol in enteric-coated capsules
Number of subjects: 8
Study 15906167 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol in rectal capsules
Number of subjects: 8
Study 15906167 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 8
Study 12641984 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide (0.5 g/kg/day, orally in bolus)
Number of subjects: 30
Study 10426876 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 0
Study 10426876 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 0
Study 10426876 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb-IIIa platelet receptor antagonists
Number of subjects: 0
Study 10426876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombolysis or thrombectomy devices
Number of subjects: 0
Study 8924442 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention curriculum taught by the teacher with trained peer leaders
Number of subjects: 223
Study 8924442 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention curriculum taught by the teacher without trained peer leaders
Number of subjects: 223
Study 8924442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 223
Study 1520545 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata (PO)
Number of subjects: 20
Study 1520545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6542371 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic factor thymostimulin (TS; Tp‐1 Serono)
Number of subjects: 37
Study 6542371 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 37
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing government subsidies
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementing clinical pathways
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing drug mark-ups
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Salary system reform
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Current income level satisfaction
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting pricing policies
Number of subjects: 178
Study 30819157 — intervention group
Group type: EXPERIMENTAL
Intervention: Removing drug markups
Number of subjects: 178
Study 29729672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish intake
Number of subjects: 306
Study 29729672 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype
Number of subjects: 306
Study 26621521 — intervention group
Group type: EXPERIMENTAL
Intervention: YOCAS©® yoga
Number of subjects: 328
Study 26621521 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 328
Study 25442152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study 25442152 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 23342565 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 84
Study 23342565 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 84
Study 23342565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 84
Study 23342565 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% NaOCl
Number of subjects: 84
Study 23342565 — intervention group
Group type: COMPARATOR
Intervention: Acid Etchant (Control)
Number of subjects: 84
Study 20515217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 72
Study 20515217 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 72
Study 18984393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implants (miniplates, miniscrews, or microscrews)
Number of subjects: 47
Study 18984393 — intervention group
Group type: COMPARATOR
Intervention: Traditional anchorage preparation with a transpalatal arch and headgear
Number of subjects: 47
Study 18984393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implants
Number of subjects: 47
Study 18984393 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal anchorage
Number of subjects: 47
Study 18984393 — intervention group
Group type: COMPARATOR
Intervention: Headgear anchorage
Number of subjects: 47
Study 15903377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and speed training program (COM group)
Number of subjects: 35
Study 15903377 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training (STR group)
Number of subjects: 35
Study 15903377 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 35
Study 12872591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral distraction devices after high LeFort I osteotomies
Number of subjects: 11
Study 12872591 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral distraction devices after LeFort I, II and III osteotomies
Number of subjects: 11
Study 10235220 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 million units alpha-N1 IFN i.m. t.w. for 24 wk (total dose: 720 million units)
Number of subjects: 72
Study 10235220 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 million units alpha-2a IFN i.m. t.w. for 4 wk, followed by 18 million units for 12 wk and 9 million units for 8 wk (972 million units)
Number of subjects: 72
Study 10235220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 alpha-2a IFN courses (9 million units i.m. t.w. for 16 and 12 wk separated by a 6-month interval [756 million units])
Number of subjects: 72
Study 10235220 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response after 34 months (median posttreatment follow-up)
Number of subjects: 72
Study 8918858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory radiology consultation service
Number of subjects: 2200
Study 8918858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mandatory consultation)
Number of subjects: 2200
Study 1859007 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG9426 0.12 mg/kg
Number of subjects: 80
Study 1859007 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG9426 0.16 mg/kg
Number of subjects: 80
Study 1859007 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG9426 0.20 mg/kg
Number of subjects: 80
Study 1859007 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG9426 0.6 mg/kg (group 1)
Number of subjects: 80
Study 1859007 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG9426 0.6 mg/kg (group 2)
Number of subjects: 80
Study 6353523 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (1 g)
Number of subjects: 54
Study 6353523 — intervention group
Group type: COMPARATOR
Intervention: secobarbital (100 mg)
Number of subjects: 54
Study 6353523 — intervention group
Group type: COMPARATOR
Intervention: flurazepam (30 mg)
Number of subjects: 54
Study 6353523 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study 31759660 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program)
Number of subjects: 120
Study 31759660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 31876460 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive preventive counseling with focus on diet modification followed by remote preventive counseling by phone every two weeks for the first 3 months (total of 6 sessions)
Number of subjects: 100
Study 31876460 — intervention group
Group type: COMPARATOR
Intervention: Usual care in Health centers including basic preventive counseling
Number of subjects: 100
Study 31876460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 28317415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (150 mg twice daily)
Number of subjects: 704
Study 28317415 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0 to 3.0)
Number of subjects: 704
Study 28317415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 704
Study 28317415 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 704
Study 28317415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran and Warfarin
Number of subjects: 704
Study 26254207 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy group (n = 121)
Number of subjects: 245
Study 26254207 — intervention group
Group type: COMPARATOR
Intervention: Repeat-PGE2 group (n = 124)
Number of subjects: 245
Study 23352688 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 63
Study 23352688 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 63
Study 22677260 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone
Number of subjects: 592
Study 22677260 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (D) 75 mg/m² every 3 weeks with prednisone and Risedronate (DR) 30 mg oral once daily
Number of subjects: 592
Study 20129543 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor drug-eluting stent
Number of subjects: 1197
Study 20129543 — intervention group
Group type: COMPARATOR
Intervention: Driver bare-metal stent
Number of subjects: 1197
Study 18019047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 0
Study 18019047 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardisation in reporting of adverse effects
Number of subjects: 0
Study 18019047 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of common side-effects
Number of subjects: 0
Study 15082437 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 19
Study 15082437 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 19
Study 12296840 — intervention group
Group type: EXPERIMENTAL
Intervention: Various cancer treatments; specific interventions not detailed; focus on quality of life measures using standardized schedules.
Number of subjects: 0
Study 12296840 — intervention group
Group type: EXPERIMENTAL
Intervention: User involvement in trials; surveys of recruitment and participation; investigations of patient preferences and experiences.
Number of subjects: 0
Study 9806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for local disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone or in combination with radiation for regional disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: COMPARATOR
Intervention: Radiation for local disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: COMPARATOR
Intervention: Radiation for distant disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for distant disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Days spent in hospital for regional disease
Number of subjects: 1706
Study 9806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Days spent in hospital for distant disease
Number of subjects: 1706
Study 7714213 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of JC virus DNA by PCR in cerebrospinal fluid
Number of subjects: 23
Study 7714213 — intervention group
Group type: COMPARATOR
Intervention: Control group without progressive multifocal leukoencephalopathy
Number of subjects: 23
Study 7714213 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR test for JC virus DNA
Number of subjects: 23
Study 1659438 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiradoline
Number of subjects: 10
Study 1659438 — intervention group
Group type: COMPARATOR
Intervention: High dose naloxone
Number of subjects: 10
Study 1659438 — intervention group
Group type: COMPARATOR
Intervention: Low dose naloxone
Number of subjects: 10
Study 7270090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquinaldol (SterosanR vaginal jelly) applied for six days before vacuum aspiration
Number of subjects: 199
Study 7270090 — intervention group
Group type: COMPARATOR
Intervention: Control group (291 women)
Number of subjects: 199
Study 30466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-radiological assessment
Number of subjects: 1345
Study 30466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-integrated assessment
Number of subjects: 1345
Study 30466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-radiological discordant results
Number of subjects: 1345
Study 30466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical-integrated discordant results
Number of subjects: 1345
Study 30466805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically assessed residual disease
Number of subjects: 1345
Study 29211194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call - educational
Number of subjects: 511
Study 29211194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call - reminder
Number of subjects: 511
Study 29211194 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (card with details)
Number of subjects: 511
Study 25826108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratitude intervention (gratitude diary and grateful reflection)
Number of subjects: 65
Study 25826108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (mindfulness diary and Body Scan meditation)
Number of subjects: 65
Study 25826108 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 65
Study 24078028 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intradermal sutures
Number of subjects: 203
Study 24078028 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 203
Study 23034962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary phylloquinone intake (100 μg phylloquinone/d)
Number of subjects: 1925
Study 23034962 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary intake of vitamin K during follow-up
Number of subjects: 1925
Study 19218829 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry Exposure (WE)
Number of subjects: 73
Study 19218829 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 73
Study 19218829 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control
Number of subjects: 73
Study 18158076 — intervention group
Group type: EXPERIMENTAL
Intervention: LM50/50 + Met
Number of subjects: 315
Study 18158076 — intervention group
Group type: COMPARATOR
Intervention: G + Met
Number of subjects: 315
Study 15465973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.1 mg/kg)
Number of subjects: 45
Study 15465973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ketamine (0.5 mg/kg)
Number of subjects: 45
Study 15465973 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study 11898532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic and behavioral components for managing fatigue in MS
Number of subjects: 0
Study 11898532 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐report scales and performance‐based measures
Number of subjects: 0
Study 9519580 — intervention group
Group type: EXPERIMENTAL
Intervention: Less violent theatrical production based on social learning theory and risk-factor reduction
Number of subjects: 0
Study 8076620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (50 g at time 0 min and 25 g at time 60 and 120 min)
Number of subjects: 6
Study 8076620 — intervention group
Group type: COMPARATOR
Intervention: Sweetened water (control)
Number of subjects: 6
Study 8076620 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 6
Study 2510269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil (300 micrograms b.d. and 600 micrograms nocte)
Number of subjects: 0
Study 2510269 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 0
Study 2510269 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 215088 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial diet for 12 months
Number of subjects: 43
Study 215088 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 43
Study 30796588 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-guided occlusion (CGO)
Number of subjects: 40
Study 30796588 — intervention group
Group type: COMPARATOR
Intervention: Bilateral balanced occlusion (BBO)
Number of subjects: 40
Study 30796588 — intervention group
Group type: COMPARATOR
Intervention: Transition from BBO to CGO
Number of subjects: 40
Study 27381968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss through a 3-month intensive behavioral weight management intervention with structured energy-restricted meal plans (1200 or 1500 kcal/day)
Number of subjects: 59
Study 27381968 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 59
Study 25881462 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Decoction (YHD), one dose daily for 14 days
Number of subjects: 46
Study 25881462 — intervention group
Group type: COMPARATOR
Intervention: Routine symptomatic treatment (Group A)
Number of subjects: 46
Study 25881462 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (18 patients with chronic cough)
Number of subjects: 46
Study 23703011 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental motor studies to the second lumbrical (2L)
Number of subjects: 20
Study 23703011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nerve action potential (MNAP) studies
Number of subjects: 20
Study 23703011 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 20
Study 23703011 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical cases (6 patients)
Number of subjects: 20
Study 20564681 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wave diathermy (SWD)
Number of subjects: 32
Study 20564681 — intervention group
Group type: COMPARATOR
Intervention: Analgesic
Number of subjects: 32
Study 20564681 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 32
Study 19136484 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3096
Study 19136484 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 3096
Study 17376219 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous retrograde sclerotherapy with hydroxy‐polyaethoxy‐dodecanol
Number of subjects: 38
Study 17376219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 15139072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan yoga (TY) intervention, 7 weekly yoga sessions
Number of subjects: 39
Study 15139072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibetan yoga (TY) intervention
Number of subjects: 39
Study 11339516 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg
Number of subjects: 1021
Study 11339516 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 1021
Study 11339516 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1021
Study 11339516 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 150 mg
Number of subjects: 1021
Study 9255145 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In/90Y-MX-DTPA BrE-3 (6.25 mCi/m2 and 9.25 mCi/m2)
Number of subjects: 6
Study 9255145 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In/90Y-MX-DTPA BrE-3
Number of subjects: 6
Study 8432915 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (50 micrograms/m2 daily subcutaneous injection for 12 weeks)
Number of subjects: 83
Study 8432915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 31711704 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg CoQ10/kg diet
Number of subjects: 36
Study 31711704 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CoQ10/kg diet
Number of subjects: 36
Study 31711704 — intervention group
Group type: COMPARATOR
Intervention: 0 mg CoQ10/kg diet (Control)
Number of subjects: 36
Study 28239945 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clips demonstrating behaviour management techniques for children receiving local anaesthetic
Number of subjects: 86
Study 28239945 — intervention group
Group type: COMPARATOR
Intervention: Standard lectures and seminars about behaviour management techniques for children having local anaesthetic
Number of subjects: 86
Study 27015659 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (4-month moderate- to hard-intensity exercise training programme, 29 one-hour classes, twice weekly)
Number of subjects: 0
Study 27015659 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (4-month moderate- to hard-intensity exercise training programme)
Number of subjects: 0
Study 27015659 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 24072136 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator drug (Omnipaque)
Number of subjects: 44
Study 24072136 — intervention group
Group type: COMPARATOR
Intervention: Generic drug (Iopaque)
Number of subjects: 44
Study 22086352 — intervention group
Group type: EXPERIMENTAL
Intervention: Integral stimuli (pictures with interacting features)
Number of subjects: 0